Search Patents
-
Patent number: 10695378Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.Type: GrantFiled: June 4, 2018Date of Patent: June 30, 2020Assignee: Duke UniversityInventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
-
Patent number: 5631237Abstract: Methods and compositions are provided for intracellular transfer of a wide variety of agents, by using Sendai virus comprising liposomes having various compositions in the liposome lumen. A preferred method for preparing the liposomes provides for enhanced levels of luminal concentrations, as well as incorporation of high molecular weight molecules. The method comprises fusing liposomes, where one liposome comprises the Sendai virus proteins and the other liposome comprises the luminal composition. The subject methods find particular application with intranuclear transfer of nucleic acids, more particularly with cells of the vasculature.Type: GrantFiled: May 10, 1994Date of Patent: May 20, 1997Inventors: Victor J. Dzau, Yasufumi Kaneda
-
Publication number: 20020128217Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signaling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: ApplicationFiled: June 5, 2001Publication date: September 12, 2002Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Publication number: 20030186922Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: ApplicationFiled: April 25, 2003Publication date: October 2, 2003Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Publication number: 20020052333Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: ApplicationFiled: April 19, 2001Publication date: May 2, 2002Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Patent number: 6821956Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: GrantFiled: April 19, 2001Date of Patent: November 23, 2004Assignee: The Brigham and Women's Hospital, Inc.Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Patent number: 5821234Abstract: This invention encompasses a method for inhibiting vascular cellular activity of cells associated with vascular lesion formation in mammals which involves administering an effective dosage of at least one antisense sequence to at least one gene expressing a cyclin or a cyclin dependent kinase which inhibits the expression of the gene. More particularly, the invention involves administering antisense sequences which inhibit the expression of cyclin A, B1, B2, C, D1, D2, D3, E or cyclin X (p46) cyclin X and cyclin dependent kinase cdc2, cdk2, cdk4 or cdk5. It is preferable to use two antisense sequences each from a different cyclin or cyclin dependent kinase. The cyclin or cyclin kinase depending kinase dosage is preferable administered in combination with proliferating cell nuclear antigen (PCNA). Antisense methods and compositions direct to inhibiting the expression of growth factors such as TGF-.beta..sub.1, TGF, bFGF, PDGF are also contemplated by the present invention.Type: GrantFiled: August 20, 1993Date of Patent: October 13, 1998Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Victor J. Dzau
-
Patent number: 5869462Abstract: This invention encompasses a method for inhibiting vascular cellular activity of cells associated with vascular lesion formation in mammals which involves administering an effective dosage of at least one antisense sequence to at least one gene expressing a cyclin or a cyclin dependent kinase which inhibits the expression of the gene. More particularly, the invention involves administering antisense sequences which inhibit the expression of cyclin A, B1, B2, C, D1, D2, D3, E or cyclin X (p46) cyclin X and cyclin dependent kinase cdc2, cdk2, cdk4 or cdk5. It is preferable to use two antisense sequences each from a different cyclin or cyclin dependent kinase. The cyclin or cyclin kinase depending kinase dosage is preferable administered in combination with proliferating cell nuclear antigen (PCNA). Antisense methods and compositions direct to inhibiting the expression of growth factors such as TGF-.beta..sub.1, TGF, bFGF, PDGF are also contemplated by the present invention.Type: GrantFiled: February 16, 1995Date of Patent: February 9, 1999Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Victor J. Dzau